Idaho Senate proposes Doug Cameron Act to suspend gene therapy immunizations

Idaho's Senate Bill 1036, introduced on January 30, 2025, aims to impose a moratorium on the use of human gene therapy products, particularly in the context of immunizations. The bill, known as the "Doug Cameron Act," is named after an Idaho rancher who suffered severe health complications following a genetic immunization. The legislation seeks to protect Idaho residents from potential adverse effects associated with experimental gene therapies.

The bill's primary provision establishes a moratorium on administering human gene therapy products for infectious disease indications. This includes any treatment categorized as an immunization or vaccine. The legislation defines human gene therapy products broadly, encompassing various genetic materials and engineered microorganisms that alter human genetic sequences.

Supporters of the bill argue that it is essential for ensuring the safety and well-being of Idahoans, emphasizing the need for caution and transparency in the deployment of such treatments. The bill reflects growing concerns over the rapid development and approval of gene therapies without sufficient long-term safety data.

Opposition to the bill may arise from advocates of gene therapy, who argue that these treatments hold significant potential for addressing various health issues, including genetic disorders and infectious diseases. Critics may contend that the moratorium could hinder medical advancements and limit access to potentially life-saving therapies.

The implications of Senate Bill 1036 could be significant, as it may set a precedent for how gene therapies are regulated in Idaho and potentially influence similar legislative efforts in other states. The bill's emergency declaration suggests that lawmakers view the issue as urgent, indicating a strong desire to act swiftly in response to public health concerns.

As the bill progresses through the legislative process, its impact on healthcare practices, patient access to innovative treatments, and the broader conversation around gene therapy will be closely monitored by stakeholders across the state.